News

ImmunityBio (IBRX) stock gains as its CAR-NK cell therapy shows promise in an early stage trial, with lymphoma patients ...
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...
Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...
In addition to Scotiabank, Biogen also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued today. However, on the same day, Truist Financial maintained a Hold rating on Biogen (NASDAQ ...
In a report released today, Jay Olson from Oppenheimer reiterated a Buy rating on Biogen, with a price target of $205.00. The company’s shares closed today at $128.00. Take advantage of TipRanks ...
Amid a cautious outlook, Biogen has presented new data at the Alzheimer’s Association International Conference (AAIC) 2025, demonstrating that investigational Leqembi 360 mg subcutaneous maintenance ...
Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...
We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...
Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...
A week ago, Biogen Inc. ( NASDAQ:BIIB ) came out with a strong set of quarterly numbers that could potentially lead ...
US biotech major Biogen (Nasdaq: BIIB) reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion.
In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...